Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Ascentage Pharma announced that olverembatinib has been granted a Breakthrough Therapy Designation by the Center for Drug Evaluation of China’s National Medical Products Administration, for combination with low-intensity chemotherapy for the treatment of patients with Philadelphia chromosome-positive ALL.